![](/img/cover-not-exists.png)
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Stellbrink, Hans-Jürgen, Arribas, José R, Stephens, Jeffrey L, Albrecht, Helmut, Sax, Paul E, Maggiolo, Franco, Creticos, Catherine, Martorell, Claudia T, Wei, Xuelian, Acosta, Rima, Collins, Sean E,Language:
english
Journal:
The Lancet HIV
DOI:
10.1016/S2352-3018(19)30080-3
Date:
May, 2019
File:
PDF, 337 KB
english, 2019